Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI:10.2217/imt-2023-0305

Monika Mach-Tomalska, Anna Pituch-Noworolska, Ewa Bień, Magdalena Malanowska, Edyta Machura, Anna Pukas-Bochenek, Ewelina Chrobak, Małgorzata Pac, Barbara Pietrucha, Szymon Drygała, Marta Kamieniak, Jakub Kasprzak, Edyta Heropolitańska-Pliszka

{"title":"Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.","authors":"Monika Mach-Tomalska, Anna Pituch-Noworolska, Ewa Bień, Magdalena Malanowska, Edyta Machura, Anna Pukas-Bochenek, Ewelina Chrobak, Małgorzata Pac, Barbara Pietrucha, Szymon Drygała, Marta Kamieniak, Jakub Kasprzak, Edyta Heropolitańska-Pliszka","doi":"10.2217/imt-2023-0305","DOIUrl":null,"url":null,"abstract":"Aim: This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (PIDs) in Poland. Methods: Clinical and demographic information, fSCIG treatment parameters and clinical outcomes were extracted from medical records of 28 participants (aged ≤18 years) with PIDs who received fSCIG. Results: 18 participants (64.3%) started fSCIG with a ramp-up (median duration: 35.5 days). 27 patients (96.4%) were administered fSCIG every 4 weeks and one patient every 3 weeks. 25 patients (89.3%) used one infusion site. No serious bacterial infections occurred. Conclusion: Data support the feasibility of administering fSCIG to children and adolescents with PIDs every 3-4 weeks using a single infusion site and indicate flexibility in modifying fSCIG infusion parameters. Clinical Trial Registration: NCT04636502 (ClinicalTrials.gov).","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"391-403"},"PeriodicalIF":2.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/imt-2023-0305","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (PIDs) in Poland. Methods: Clinical and demographic information, fSCIG treatment parameters and clinical outcomes were extracted from medical records of 28 participants (aged ≤18 years) with PIDs who received fSCIG. Results: 18 participants (64.3%) started fSCIG with a ramp-up (median duration: 35.5 days). 27 patients (96.4%) were administered fSCIG every 4 weeks and one patient every 3 weeks. 25 patients (89.3%) used one infusion site. No serious bacterial infections occurred. Conclusion: Data support the feasibility of administering fSCIG to children and adolescents with PIDs every 3-4 weeks using a single infusion site and indicate flexibility in modifying fSCIG infusion parameters. Clinical Trial Registration: NCT04636502 (ClinicalTrials.gov).

查看原文本刊更多论文

原发性免疫缺陷病儿科患者的皮下注射免疫球蛋白治疗模式。

目的：这项回顾性研究调查了波兰原发性免疫缺陷病（PID）儿科患者的透明质酸酶促进皮下免疫球蛋白（fSCIG）实际治疗模式。方法：从 28 名接受 fSCIG 治疗的 PID 患者（年龄小于 18 岁）的病历中提取临床和人口统计学信息、fSCIG 治疗参数和临床结果。结果显示18名参试者（64.3%）开始接受 fSCIG 治疗（中位持续时间：35.5 天）。27 名患者（96.4%）每 4 周接受一次 fSCIG 治疗，1 名患者每 3 周接受一次 fSCIG 治疗。25 名患者（89.3%）使用一个输注部位。没有发生严重的细菌感染。结论数据支持每 3-4 周使用单一输注部位给患有 PID 的儿童和青少年注射 fSCIG 的可行性，并表明可以灵活调整 fSCIG 输注参数。临床试验注册：NCT04636502（ClinicalTrials.gov）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.